Proof of concept for a banding scheme to support risk assessments related to multi-product biologics manufacturing
A banding scheme theory has been proposed to assess the potency/toxicity of biologics and assist with decisions regarding the introduction of new biologic products into existing manufacturing facilities. The current work was conducted to provide a practical example of how this scheme could be applie...
Gespeichert in:
Veröffentlicht in: | Regulatory toxicology and pharmacology 2015-11, Vol.73 (2), p.595-606 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | A banding scheme theory has been proposed to assess the potency/toxicity of biologics and assist with decisions regarding the introduction of new biologic products into existing manufacturing facilities. The current work was conducted to provide a practical example of how this scheme could be applied. Information was identified for representatives from the following four proposed bands: Band A (lethal toxins); Band B (toxins and apoptosis signals); Band C (cytokines and growth factors); and Band D (antibodies, antibody fragments, scaffold molecules, and insulins). The potency/toxicity of the representative substances was confirmed as follows: Band A, low nanogram quantities exert lethal effects; Band B, repeated administration of microgram quantities is tolerated in humans; Band C, endogenous substances and recombinant versions administered to patients in low (interferons), intermediate (growth factors), and high (interleukins) microgram doses, often on a chronic basis; and Band D, endogenous substances present or produced in the body in milligram quantities per day (insulin, collagen) or protein therapeutics administered in milligram quantities per dose (mAbs). This work confirms that substances in Bands A, B, C, and D represent very high, high, medium, and low concern with regard to risk of cross-contamination in manufacturing facilities, thus supporting the proposed banding scheme.
•Carryover cross-contamination is a risk in multi-product manufacturing facilities.•A banding scheme for potency/toxicity of biologics has recently been proposed.•Information was identified and reviewed to determine the banding scheme feasibility.•Bands for substances of low, medium, high, and very high concern can be delineated.•The bands can be used to support risk assessments related to cross-contamination. |
---|---|
ISSN: | 0273-2300 1096-0295 |
DOI: | 10.1016/j.yrtph.2015.09.003 |